Physician

Randy S Rich, MD

According to 2025 Medicare claims, Randy Rich, MD (NPI: 1609863281) practices hematology/oncology in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Cook, IL. This provider's primary affiliated billing organization is ILLINOIS CANCER SPECIALISTS (NPI: 1164483913; TIN: 363980044) and primary practice location at 60005-2380.

Rich's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 707 traditional Medicare patients, billed 195,147 HCPCS/CPT codes, and received $3,333,373 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,218 prescription claims across 224 beneficiaries totaling $1,385,132 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 85 claims. Open Payments data shows 23 records totaling $757. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $897,570 to $1,385,132. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $26,527 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	680	229,040	$2,425,914
2016	678	213,608	$2,628,644
2017	658	181,889	$2,293,908
2018	804	181,325	$2,506,758
2019	813	219,764	$3,253,361
2020	669	177,589	$2,683,654
2021	722	161,220	$2,823,104
2022	712	180,401	$2,529,360
2023	673	191,190	$2,980,670
2024	707	195,147	$3,333,373

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	216	1,722	$897,570
2016	220	1,756	$794,287
2017	224	1,529	$1,085,591
2018	235	1,525	$1,609,754
2019	275	1,791	$1,823,809
2020	254	1,759	$2,019,056
2021	242	1,577	$1,794,525
2022	246	1,370	$1,576,348
2023	229	1,287	$1,859,596
2024	224	1,218	$1,385,132

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	36	344	$31,122
2016	N/R	123	$19,996
2017	N/R	23	$831
2018	N/R	73	$32,449
2019	N/R	12	$397
2020	N/R	N/R	N/R
2021	N/R	85	$47,979
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	102	406	$103
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	184	616	$98
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	301	493	$66
36415	Insertion of needle into vein for collection of blood sample	511	1,411	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	542	2,062	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	19	532	$316,336
Calquence	Acalabrutinib Maleate	19	570	$309,322
Brukinsa	Zanubrutinib	12	360	$186,828
Lenalidomide	Lenalidomide	12	336	$144,293
Eliquis	Apixaban	128	5,937	$113,581

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	23	$757	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Randy S. Rich, MD?

Tedicare shows public-source Medicare data for Randy S. Rich, MD (NPI 1609863281), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Randy S. Rich, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Randy S. Rich, MD?

Randy S. Rich, MD is linked to ILLINOIS CANCER SPECIALISTS (billing NPI 1164483913) in the available physician profile data.

Does Randy S. Rich, MD have Open Payments data?

Randy S. Rich, MD has 23 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.